ArticleMolecular and cellular biology2005
Role of epidermal growth factor receptor signaling in RAS-driven melanoma.
Article in Molecular and cellular biology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Guidelines for biomarker testing in metastatic melanoma: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2014Guideline
- Non-canonical EGFR signaling promotes MAPK-dependent extrusion of epithelial cells.Journal of cell science · 2025Article
- Current understanding of epigenetics role in melanoma treatment and resistance.Cancer cell international · 2022Review
- WIPI1 promotes fission of endosomal transport carriers and formation of autophagosomes through distinct mechanisms.Autophagy · 2021Article
- EGFRAP encodes a new negative regulator of the EGFR acting in both normal and oncogenic EGFR/Ras-driven tissue morphogenesis.PLoS genetics · 2021Article
- Aloysia Citrodora Essential Oil Inhibits Melanoma Cell Growth and Migration by Targeting HB-EGF-EGFR Signaling.International journal of molecular sciences · 2021Article
- Effects of somatic alterations at pathway level are more mechanism-explanatory and clinically applicable to quantity of liver metastases of colorectal cancer.Cancer medicine · 2019Article
- Reversal of Resistance in Targeted Therapy of Metastatic Melanoma: Lessons Learned from Vemurafenib (BRAFCancers · 2018Review
- EGFR/ARF6 regulation of Hh signalling stimulates oncogenic Ras tumour overgrowth.Nature communications · 2017Article
- The melanoma revolution: from UV carcinogenesis to a new era in therapeutics.Science (New York, N.Y.) · 2014Review
- Aberrant apoptotic machinery confers melanoma dual resistance to BRAF(V600E) inhibitor and immune effector cells: immunosensitization by a histone deacetylase inhibitor.American journal of clinical and experimental immunology · 2014Article
- The matrikine tenascin-C protects multipotential stromal cells/mesenchymal stem cells from death cytokines such as FasL.Tissue engineering. Part A · 2013Article
- MAP kinase signaling and inhibition in melanoma.Oncogene · 2013Review
- Hyperactivation of constitutively dimerized oncogenic EGF receptors by autocrine loops.Oncogene · 2013Article
- EGF receptor is required for KRAS-induced pancreatic tumorigenesis.Cancer cell · 2012Article
- Drug targets and predictive biomarkers in the management of metastatic melanoma.Pharmacogenomics and personalized medicine · 2012Article
- Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis.Oncogene · 2010Article
- Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis.Small GTPases · 2010Article
- MMP13 mediates cell cycle progression in melanocytes and melanoma cells: in vitro studies of migration and proliferation.Molecular cancer · 2010Article
- Recent advances on skin-resident stem/progenitor cell functions in skin regeneration, aging and cancers and novel anti-aging and cancer therapies.Journal of cellular and molecular medicine · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The identification of essential genetic elements in pathways governing the maintenance of fully established tumors is critical to the development of effective antioncologic agents. Previous studies revealed an essential role for H-RAS(V12G) in melanoma maintenance in an inducible transgenic model. Here, we sought to define the molecular basis for RAS-dependent tumor maintenance through determination of the H-RAS(V12G)-directed transcriptional program and subsequent functional validation of potential signaling surrogates. The extinction of H-RAS(V12G) expression in established tumors was associated with alterations in the expression of proliferative, antiapoptotic, and angiogenic genes, a profile consistent with the observed phenotype of tumor cell proliferative arrest and death and endothelial cell apoptosis during tumor regression. In particular, these melanomas displayed a prominent RAS-dependent regulation of the epidermal growth factor (EGF) family, leading to establishment of an EGF receptor signaling loop. Genetic complementation and interference studies demonstrated that this signaling loop is essential to H-RAS(V12G)-directed tumorigenesis. Thus, this inducible tumor model system permits the identification and validation of alternative points of therapeutic intervention without neutralization of the primary genetic lesion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.